ArticleFrontiers in medicine2021
Detection of Parkinson's Disease Through Automated Pupil Tracking of the Post-illumination Pupillary Response.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07748715 (Blue Color Processing in the Eye as a Biomarker of Brain Dopamine), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Blue Color Processing in the Eye as a Biomarker of Brain Dopamine
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Recent advances (2022-2024) in eye-tracking for Parkinson's disease: a promising tool for diagnosing and monitoring symptoms.Frontiers in aging neuroscience · 2025Pooled it
- Improving Parkinson's disease diagnosis by non-invasive detection of retinal biomarkers in MPTP monkeys using ERG and pupillometry.NPJ Parkinson's disease · 2026Article
- Circadian Rhythms in Aging and Age-Related Neurogenerative Disease.Current sleep medicine reports · 2025Article
- A rapid pupillometry protocol for clinical use: effect of age and test-retest repeatability.Documenta ophthalmologica. Advances in ophthalmology · 2025Article
- A rapid pupillometry protocol for clinical use: Effect of age and test-retest repeatability.Research square · 2025Article
- Eye Tracking in Parkinson's Disease: A Review of Oculomotor Markers and Clinical Applications.Brain sciences · 2025Review
- Integrating Assessment of Circadian Rhythmicity to Improve Treatment Outcomes for Circadian Rhythm Sleep-Wake Disorders: Updates on New Treatments.Current sleep medicine reports · 2025Review
- Digital biomarkers for precision diagnosis and monitoring in Parkinson's disease.NPJ digital medicine · 2024Review
- Retinal Changes in Parkinson's Disease: A Non-invasive Biomarker for Early Diagnosis.Cellular and molecular neurobiology · 2023Review
- Application of Pupillometry in Neurocritical Patients.Journal of personalized medicine · 2023Review
- Machine Learning and Eye Movements Give Insights into Neurodegenerative Disease Mechanisms.Sensors (Basel, Switzerland) · 2023Review
- Chromatic pupillometry for evaluating melanopsin retinal ganglion cell function in Alzheimer's disease and other neurodegenerative disorders: a review.Frontiers in psychology · 2023Review
- Variable abnormality of the melanopsin-derived portion of the pupillary light reflex (PLR) in patients with Parkinson's disease (PD) and parkinsonism features.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Pupil Size Prediction Techniques Based on Convolution Neural Network.Sensors (Basel, Switzerland) · 2021Article
- Memory Deficit in Patients With Temporal Lobe Epilepsy: Evidence From Eye Tracking Technology.Frontiers in neuroscience · 2021Article
- PupilEXT: Flexible Open-Source Platform for High-Resolution Pupillometry in Vision Research.Frontiers in neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is one of the most common neurodegenerative disorders, but it is often diagnosed after the majority of dopaminergic cells are already damaged. It is critical to develop biomarkers to identify the disease as early as possible for early intervention. PD patients appear to have an altered pupillary response consistent with an abnormality in photoreceptive retinal ganglion cells. Tracking the pupil size manually is a tedious process and offline automated systems can be prone to errors that may require intervention; for this reason in this work we describe a system for pupil size estimation with a user interface to allow rapid adjustment of parameters and extraction of pupil parameters of interest for the present study. We implemented a user-friendly system designed for clinicians to automate the process of tracking the pupil diameter to measure the post-illumination pupillary response (PIPR), permit manual corrections when needed, and continue automation after correction. Tracking was automated using a Kalman filter estimating the pupil center and diameter over time. The resulting system was tested on a PD classification task in which PD subjects are known to have similar responses for two wavelengths of light. The pupillary response is measured in the contralateral eye to two different light stimuli (470 and 610 nm) for 19 PD and 10 control subjects. The measured Net PIPR indicating different responsiveness to the wavelengths was 0.13 mm for PD subjects and 0.61 mm for control subjects, demonstrating a highly significant difference (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.